Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | MTHFD1 | P11586 | 2/20 | 0.54 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.48 |
| ▸ | MTHFD2 | P13995 | 2/20 | 0.44 |
| ▸ | FPGS | Q05932 | 2/20 | 0.44 |
| ▸ | TYMS | P04818 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | GART | P22102 | 4/20 | 0.39 |
| ▸ | ATIC | P31939 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24179695 | 1.00 | DHFR (0.74) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| SCHEMBL24179667 | 0.89 | MTHFD1 (0.65) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| SCHEMBL18499953 | 0.89 | MTHFD1 (0.65) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| SCHEMBL17500357 | 0.86 | DHFR (0.72) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| SCHEMBL17500359 | 0.86 | DHFR (0.72) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| SCHEMBL3408027 | 0.86 | DHFR (0.72) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Folinic Acid SCHEMBL21498299 | 0.85 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| SCHEMBL18402509 | 0.85 | DHFR (0.83) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Leucovorin SCHEMBL36113 | 0.85 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Leucovorin SCHEMBL3031362 | 0.85 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190111059-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTISM SPECTRUM DISORDER | MARINUS PHARMACEUTICALS, INC. (US) | 2019-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190111059-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTISM SPECTRUM DISORDER | SLC19A1, FOLR2, FOLR1 | DHFR 7/4885LMNA 3795/4885MTHFD1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.